Overview

Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer

Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiotherapy is currently the most efficient way to induce pathologic responses, which are associated with a favorable prognosis in localized tumors. Novel radiotherapy techniques are associated with significantly less toxicity than traditional radiation protocols and permit to avoid the toxicity to adjacent organs. Established chemotherapy regimens, such as cisplatin and capecitabine, and monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving radiation therapy together with cisplatin and cetuximab before surgery aims to induce a pathological response and improve the prognosis after surgery. PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy when given together with cisplatin and cetuximab in treating patients who are undergoing surgery for locally advanced gastric cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dr Anna Dorothea Wagner
Treatments:
Capecitabine
Cetuximab
Cisplatin